Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.52)
# 265
Out of 5,241 analysts
234
Total ratings
54.29%
Success rate
21.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Maintains: Equal-Weight | $14 → $16 | $12.86 | +24.42% | 6 | May 14, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Equal-Weight | $185 → $191 | $157.21 | +21.49% | 34 | May 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $90 → $103 | $75.18 | +37.00% | 15 | May 6, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $50 → $67 | $24.19 | +176.97% | 10 | Apr 16, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $13 → $12 | $4.36 | +175.23% | 7 | Apr 8, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $150 → $136 | $86.84 | +56.61% | 15 | Mar 17, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $225 → $226 | $229.55 | -1.55% | 13 | Feb 25, 2026 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $90 → $92 | $70.15 | +31.15% | 14 | Feb 23, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $34.70 | +130.55% | 4 | Jan 6, 2026 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $15.34 | -21.77% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $1.57 | +1,110.19% | 5 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $79 | $62.93 | +25.54% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $14.87 | +88.30% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $10.27 | -80.53% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $20.69 | +16.00% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $66.89 | +27.08% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $39.64 | -31.89% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $3.04 | +1,051.32% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $4.34 | -7.83% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.13 | +253.98% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $4.87 | +187.47% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.17 | +57.73% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $3.13 | -4.15% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $0.7984 | +1,152.51% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $49.84 | -55.86% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $8.49 | +1,649.12% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.8452 | +6,998.91% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.53 | +69.97% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $9.25 | +6,905.41% | 6 | May 8, 2020 |
Contineum Therapeutics
May 14, 2026
Maintains: Equal-Weight
Price Target: $14 → $16
Current: $12.86
Upside: +24.42%
Neurocrine Biosciences
May 6, 2026
Maintains: Equal-Weight
Price Target: $185 → $191
Current: $157.21
Upside: +21.49%
Cytokinetics
May 6, 2026
Maintains: Overweight
Price Target: $90 → $103
Current: $75.18
Upside: +37.00%
Ultragenyx Pharmaceutical
Apr 16, 2026
Maintains: Overweight
Price Target: $50 → $67
Current: $24.19
Upside: +176.97%
Bicycle Therapeutics
Apr 8, 2026
Maintains: Equal-Weight
Price Target: $13 → $12
Current: $4.36
Upside: +175.23%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Overweight
Price Target: $150 → $136
Current: $86.84
Upside: +56.61%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $225 → $226
Current: $229.55
Upside: -1.55%
PTC Therapeutics
Feb 23, 2026
Maintains: Overweight
Price Target: $90 → $92
Current: $70.15
Upside: +31.15%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $34.70
Upside: +130.55%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $15.34
Upside: -21.77%
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $1.57
Upside: +1,110.19%
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $62.93
Upside: +25.54%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $14.87
Upside: +88.30%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $10.27
Upside: -80.53%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $20.69
Upside: +16.00%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $66.89
Upside: +27.08%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $39.64
Upside: -31.89%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $3.04
Upside: +1,051.32%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $4.34
Upside: -7.83%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.13
Upside: +253.98%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $4.87
Upside: +187.47%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.17
Upside: +57.73%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $3.13
Upside: -4.15%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $0.7984
Upside: +1,152.51%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $49.84
Upside: -55.86%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $8.49
Upside: +1,649.12%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.8452
Upside: +6,998.91%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.53
Upside: +69.97%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $9.25
Upside: +6,905.41%